Articles by Becky Shadle
A business savvy Seattle native who has run a successful Seattle based business for 9 years. Becky likes to keep a close watch on the Biotechnolgy sector and maintains long term hold positions (20% portfolio) and enjoys the high risks and the lucrative returns. She likes to keep watch on companies in all stages of FDA drug approval. Combining key information with an unemotional view she hopes that you might be able to spot some big opportunities in the biotech sector.
Somaxon Pharmaceuticals, Inc (NASDAQ:SOMX) has announced that they have scheduled to meet with the US Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor which will …
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) has announced that they have set Wednesday, January 27, 2010 as the date of the special meeting of stockholders to vote on the proposed sale of its specialty pharmaceutical business to …
Emisphere Technologies Inc (OTC:EMIS) has announced that an independent Data Monitoring Committee (DMC) has informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis (OP) Phase 3 study and the …
Allos Therapeutics Inc (NASDAQ:ALTH) has reported a new analysis of data from the pivotal PROPEL trial of FOLOTYN in patients who are suffering from relapsed and refractory peripheral T-cell lymphoma (PTCL).
Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which will be held …
Origin Agritech Limited (NASDAQ:SEED) has announced that they have commenced operation of a new hybrid seed drying facility this fall harvest season.
PolyMedix Inc (OTC:PYMX) have announced the pricing of a registered public offering of up to 21,000,000 units consisting of shares and warrants for $1.00 per unit, or a total of up to US$21 million in …
IntriCon Corporation (NASDAQ:IIN) announced that they will soon unveil a prototype of their new Cardiac Diagnostic Monitoring (CDM) device called the Mobile Patient ECG Telemetry System or MPETS.
Enzon Pharmaceuticals, Inc (NASDAQ:ENZN) has announced that they have entered into a definitive agreement to sell their specialty pharmaceutical business to Sigma-Tau Group for US$300 million along with milestone payments of US$27 million.
Entest Biomedical Inc (OTC:ENTB) announced that the Company’s unique treatments for Chronic Obstructive Pulmonary Disease also known as COPD, which is currently under development, can lead to substantial revenue opportunities in the near future.
